JAMA : the journal of the American Medical Association
-
Immune dysregulation contributes to poorer outcomes in COVID-19. ⋯ Time to recovery from COVID-19 pneumonia among hospitalized participants was not significantly different for abatacept, cenicriviroc, or infliximab vs placebo.